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Abstract
Background:  To examine the outcomes and risk factors in pediatric differentiated thyroid
carcinoma (DTC) patients who were defined as TNM stage I because some patients develop
disease recurrence but treatment strategy for such stage I pediatric patients is still controversial.
Methods: We reviewed 57 consecutive TNM stage I patients (15 years or less) with DTC (46
papillary and 11 follicular) who underwent initial treatment at Ito Hospital between 1962 and 2004
(7 males and 50 females; mean age: 13.1 years; mean follow-up: 17.4 years). Clinicopathological
results were evaluated in all patients. Multivariate analysis was performed to reveal the risk factors
for disease-free survival (DFS) in these 57 patients.
Results: Extrathyroid extension and clinical lymphadenopathy at diagnosis were found in 7 and 12
patients, respectively. Subtotal/total thyroidectomy was performed in 23 patients, modified neck
dissection in 38, and radioactive iodine therapy in 10. Pathological node metastasis was confirmed
in 37 patients (64.9%). Fifteen patients (26.3%) exhibited local recurrence and 3 of them also
developed metachronous lung metastasis. Ten of these 15 achieved disease-free after further
treatments and no patients died of disease. In multivariate analysis, male gender (p = 0.017),
advanced tumor (T3, 4a) stage (p = 0.029), and clinical lymphadenopathy (p = 0.006) were risk
factors for DFS in stage I pediatric patients.
Conclusion: Male gender, tumor stage, and lymphadenopathy are risk factors for DFS in stage I
pediatric DTC patients. Aggressive treatment (total thyroidectomy, node dissection, and RI
therapy) is considered appropriate for patients with risk factors, whereas conservative or stepwise
approach may be acceptable for other patients.
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Background
Differentiated thyroid carcinoma (DTC) is rare in pediat-
ric patients. The incidence of this form has been reported
to range from 2.6% to 12.9% of whole DTC population
treated during the same period [1-11]. Papillary thyroid
carcinoma (PTC) is the most common thyroid malig-
nancy in pediatric patients as well as in adult patients [1-
35]. Radiation exposure in infancy has been reported to
be associated with the possible occurrence of PTC [12,13].
Follicular thyroid carcinoma (FTC) is the next common
form, but is usually quite rare in pediatric patients.
Advanced tumor manifestations, such as large or extensive
tumor, multifocality, lymphadenopathy, and synchro-
nous lung metastasis at diagnosis, are more evident and
are indicated to be risk factors in pediatric patients [6,14-
18]. In addition, the lower age population develops a
worse prognosis compared to young adult or adolescent
patients [11,15,17,19-22]. Therefore, total or near total
thyroidectomy followed by radioactive iodine (RI) ther-
apy is recommended as the optimal treatment strategy [1-
7,12,18-20,23-28]. However, others advocate that less
aggressive treatment is sufficient and that the extent of sur-
gery is not related to the clinical outcome [8,9,22,29-34].
Additionally, extended surgery increases the potential risk
for surgical complications, such as recurrent laryngeal
nerve (RLN) injury or permanent hypoparathyroidism
[21,23,32]. Thus, because of the clinical discrepancy
between aggressive manifestation and better outcomes,
controversy still remains concerning the appropriate treat-
ment for pediatric DTC patients. The American Joint
Committee on Cancer (AJCC)/International Union
Against Cancer (UICC) tumor-node-metastasis (TNM)
staging system defines pediatric DTC patients as TNM
stage I or stage II according to the presence or absence of
synchronous distant metastasis, regardless of the degree of
extrathyroid extension or lymph node metastases. In gen-
eral, stage II patients receive total thyroidectomy followed
by RI therapy and their lung metastases well respond to RI
treatment [4,11,14,16,19-21,25,27,33,34]. On the other
hand, the treatment strategy for stage I pediatric patients
remains controversial; a more conservative approach may
be suitable for these patients [8,9,22,26,29-34]. In this
study we therefore analyzed the risk factors in stage I pedi-
atric DTC patients.
Methods
Patient
Between 1962 and 2004, 68 pediatric patients (≤ 15 years)
with DTC were initially treated at Ito Hospital, which has
a special interest in thyroid disease. Among the 68 consec-
utive patients, 11 patients were defined as TNM stage II
because of the presence of synchronous lung metastasis.
The remaining 57 TNM stage I patients (7 males and 50
females) were reviewed in this study. The mean age (mean
± standard deviation [SD]) was 13.1 ± 2.3 (range: 7-15)
years. The mean follow-up period was 17.4 ± 10.9 (range:
0.7-45.0) years. In 42 patients (73.7%), the duration of
follow-up was over 10 years. Their mean height and body
weight were 152.7 ± 12.4 (range: 118.3-172.0) cm and
45.4 ± 12.2 (range: 18.0-73.0) kg, respectively. All 57
patients in our series underwent initial treatment at our
institution and none of the patients had undergone any
previous treatment for DTC elsewhere. Thus, patients with
any prior management before diagnosis and therapy in
our institution were excluded from the present analysis.
Histology
There were 46 PTCs including 2 follicular variant types
and 11 FTCs. Overall, the primary tumor size was 4.3 ± 2.0
cm. Specific variants, such as follicular variant of papillary
carcinoma, solid and trabecular pattern, squamous meta-
plasia or marked psammoma bodies, were found in 15
patients. Hürthle cell carcinoma or insular carcinoma was
not found in our series. Medullary thyroid carcinoma or
anaplastic thyroid carcinoma were excluded.
Clinical manifestation at diagnosis
The clinical manifestations at diagnosis were thyroid mass
in 53 (93.0%), extrathyroid extension in 7 (12.3%), clin-
ical lymphadenopathy in 12 (21.1%), and hoarseness due
to RLN palsy in 2 (3.5%) of all 57 patients. No patients
presented with synchronous lung metastasis at diagnosis
but three patients developed metachronous lung metasta-
sis in the follow up period. In only one patient, PTC was
incidentally found by ultrasound examination due to
screening during the treatment for Graves' disease.
Family or radiation history
Eleven patients had a family history of thyroid disease
(PTC in one, benign thyroid tumor such as adenomatous
goiter or follicular adenoma in 6, and Graves's disease in
4). There were no patients who had previous radiation
exposure to the head and neck.
Preoperative diagnostic modality
Fine needle aspiration biopsy cytology (FNABC) has been
performed since 1974 and ultrasound (US) examination
has been performed as a routine preoperative practice to
study primary thyroid tumor and regional lymph nodes
since 1980 at Ito Hospital. US-guided FNABC has also
been performed as a novel diagnostic tool since 1998.
Overall, FNABC was performed preoperatively in 36
patients. Cytological diagnoses were PTC, strongly sus-
pected PTC, suspected FTC, and follicular adenoma in 25,
2, 3, and 6 of the 36 patients, respectively. Consequently,
conventional or US-guided FNABC contributed to the
diagnosis of thyroid carcinoma in 30 of 36 (83.3%)
patients before surgery.
Chest X-ray was preoperatively performed as one of the
routine examinations for total anesthesia and as a screen-
ing purpose of apparent lung metastasis in all patients.BMC Cancer 2009, 9:306 http://www.biomedcentral.com/1471-2407/9/306
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Computed tomography (CT) scan was also performed
before surgery to evaluate local disease and the presence
or absence of synchronous lung metastasis since 1987.
The level of serum thyroglobulin (Tg) was measured since
1981 and the presence of Tg antibody was evaluated since
1994. In 7 patients, the information of serum Tg was not
available. Finally, the level of serum Tg was considered
reliable in 15 patients without Tg antibody at the end of
follow-up. Thus, the serum Tg was valuable to diagnose
disease recurrence or progression only in selected patients
in our series. Therefore, the level of serum Tg was not eval-
uated statistically in this study.
Surgical treatment
Lobectomy and subtotal or total thyroidectomy were per-
formed in 25 and 21 of 46 PTC patients, and in 9 and 2 of
11 FTC patients, respectively. Of the 46 PTC patients, 10,
1, 31, and 4 patients underwent no dissection, only cen-
tral node dissection, ipsilateral modified neck dissection
(MND), and bilateral MND, respectively. Of the 11 FTC
patients, 6, 2, and 3 patients underwent no dissection,
only central node dissection, and ipsilateral MND, respec-
tively. MND was defined as systematic node dissection in
the central compartment (level VI) and ipsilateral lateral
compartment (level II to V). Fundamentally, lobectomy
was performed in patients with unifocal and unilateral
tumor, no clinical lymphadenopathy, and no distant
metastasis at diagnosis. Total thyroidectomy was per-
formed in patients with multifocal or invasive tumor, clin-
ical lymphadenopathy, or distant metastasis at diagnosis.
Subtotal thyroidectomy was performed to avoid surgical
complications, such as permanent hypoparathyroidism or
RLN palsy, in selected patients who were basically candi-
dates for total thyroidectomy. For example, patients pre-
senting with ipsilateral RLN palsy underwent less total
thyroidectomy to prevent bilateral RLN palsy. MND was
usually performed in patients with advanced tumor stage
or lymphadenopathy, whereas no or only central node
dissection was performed in those with lower tumor stage
or no lymphadenopathy.
Pathological diagnosis and TNM staging
Primary tumors and regional lymph nodes were removed
in all patients and those specimens were pathologically
confirmed to be PTCs or FTCs and nodal metastases.
The sixth edition of the AJCC/UICC TNM classification
was used to determine the tumor (T) stage, nodal (N)
stage, distant metastasis (M) stage, and TNM staging.
Among the 68 pediatric patients, 57 patients without syn-
chronous distant metastasis were defined as TNM stage I
and were analyzed statistically in this study. Eleven
patients with synchronous lung metastasis were defined
as TNM stage II and were excluded from the present anal-
ysis.
Radiotherapy
Therapeutic RI treatment has principally been performed
when refractory nodal recurrence was observed or when
distant metastasis was detected visually by chest X-ray or
CT scan. Overall, 6 patients underwent RI ablation and 4
patients received therapeutic dose of RI because 3 patients
developed both nodal recurrence and metachronous lung
metastasis and one patient developed nodal recurrence.
External beam radiation therapy (EBRT) was performed
for only one patient.
TSH suppression therapy
TSH suppression therapy was administered to all patients
but it was adequately maintained in 48 of 57 patients. In
the remaining 9 patients, TSH suppression was inade-
quate due to patient compliance, or was not maintained
because of the curability of the disease (unilateral tumor
and no pathological node metastasis). These 9 patients
did not develop any recurrent disease at the time of the
present analysis.
Therapeutic complications
Overall, permanent surgical complications considered
iatrogenic were found in 9 (15.8%) of 57 patients. Perma-
nent hypoparathyroidism was observed in 6 (10.5%)
patients (subtotal thyroidectomy in one and total thyroid-
ectomy in 5). RLN palsy considered due to the nerve
injury not due to the potential risk of primary disease was
observed in 3 (5.3%) patients (subtotal thyroidectomy in
one and total thyroidectomy in 2). None of the 10
patients (3 males and 7 females) who received RI ablation
or therapy developed any other secondary malignant dis-
ease. Among the 7 female patients, 2 patients experienced
3 healthy deliveries.
Follow-up and definition of disease recurrence
Patient follow-up was generally performed every 6
months after a relatively stable condition was obtained.
Recurrent disease was defined as local recurrence (rem-
nant thyroid tissue or regional lymph node) or meta-
chronous distant metastasis that developed as new disease
during the follow-up period, at least 6 months after the
initial surgery. Recurrence was detected by physical and
radiological examinations, including US, chest X-ray, CT
scan, and/or scintigraphy, and blood test to screen for ele-
vation of the serum Tg in patients treated with total thy-
roidectomy.
Evaluation of outcomes
Clinicopathological features, treatments, and outcomes,
such as age stratification (≤ 13 years old), male gender,
histology (papillary carcinoma), specific variant, tumor
size (>3.0 cm), extrathyroid extension, multifocality,
tumor stage (T3, 4a), clinical lymphadenopathy (cN),
pathological node metastasis (pN), the extent of thyroidBMC Cancer 2009, 9:306 http://www.biomedcentral.com/1471-2407/9/306
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resection and node dissection, surgical complications,
and the rates of disease recurrence and mortality were
evaluated. These factors were compared between patients
who developed recurrence and those who did not. Dis-
ease-free survival (DFS) was evaluated in all and univari-
ate and multivariate analyses were then performed to
reveal risk factors for DFS. Disease-specific survival was
not evaluated because no patients died of disease. This
study was approved by the Ethical boards of our institu-
tion. Informed consent was obtained from patients and
their parents.
Statistical analysis
The results are expressed as the mean ± standard deviation
(SD). Frequencies were compared with the chi-square test
and Fisher's exact probability test. DFS was assessed with
the Kaplan-Meier method and compared with the log-
rank test. The effects of each risk factor on DFS were eval-
uated by multivariate analysis using the Cox proportional
hazards models [Hazard ratio (HR), 95% confidence
interval (CI)]. Differences were considered statistically sig-
nificant when p-values were less than 0.05. Statistical
analyses were performed with SPSS, version 11.0.
Results
Clinicopathological features and outcomes
Table 1 summarizes the clinicopathological features and
outcomes. 26.3% (15 patients) exhibited recurrent dis-
ease (local in 12 and both local and lung metastasis in 3).
In the 15 patients (regional node recurrence in 13 and
both remnant thyroid and regional node recurrence in 2),
the clearance of local recurrences was achieved success-
fully. After the treatment for recurrence, 10 of the 15
patients are currently free of disease. Four patients with
nodal recurrence and one patient with both nodal recur-
rence and lung metastasis are alive with disease.
Risk factor analysis
As shown in Table 1, male gender (p = 0.011), multifocal-
ity (p = 0.010), cN (p = 0.009), and pN (p = 0.040) dif-
fered significantly between patients who developed
recurrence and those who did not.
DFS Kaplan-Meier curves in 57 stage I patients are shown
in Figure 1. DFS curves significantly differed according to
gender (Fig. 1A), tumor stage (Fig. 1B), multifocality (Fig.
1C), and cN (Fig. 1D). These risk factors showed statistical
significance by univariate analysis. In multivariate analy-
sis, male gender (p = 0.017, HR 4.51, 95%CI: 1.31-15.5),
tumor stage (p = 0.029, HR 1.06, 95%CI: 1.01-1.12), and
cN (p = 0.006, HR 4.77, 95%CI: 1.55-14.7) were signifi-
cant risk factors for DFS in stage I patients, as shown in
Table 2.
Discussion
Demographically, the incidence of pediatric DTC patients
ranged from 2.6% to 12.9% of the whole DTC population
[1-11]. PTC is the most common histological type of thy-
roid carcinoma in pediatric patients, whereas FTC is
uncommonly found [1-35]. In our series, PTCs and FTCs
were found in 46 patients (80.7%) and in 11 patients
(19.3%), respectively. Moreover, none of these 11 FTCs
presented with distant metastasis both at diagnosis and
during the follow-up period and they developed a better
prognosis than PTCs. This was in concordance with the
results of previous studies [14,28]. Radiation exposure is
considered to be etiologically associated with the occur-
rence of PTC and the incidence outside of the Belarus
region usually ranges from 0% to 20% [1-7,11,12,15-
17,19-28,33,35]. Spinelli et al. [12] and Viswathan et al.
[13] suggested that radiation-induced thyroid carcinomas
are at risk for worse prognosis.
Table 1: Clinicopathological features in 57 TNM stage I pediatric DTC patients
Recurrence
Clinicopathological features Total (n = 57) Yes (n = 15) No (n = 42) P-value
No. % No. % No. %
Age (≤13) 23 40.4 8 53.3 15 35.7 NS
Male gender 7 12.3 5 33.3 2 4.8 0.011
Histology (papillary carcinoma) 46 80.7 15 100.0 31 73.8 NS
Specific variant 15 26.3 4 26.7 11 26.2 NS
Tumor size (>3.0 cm) 38 66.7 10 66.7 28 66.7 NS
Extrathyroid extension 7 12.3 3 20.0 4 9.5 NS
Multifocality 18 31.6 9 60.0 9 21.4 0.010
Tumor stage (T3, T4a) 30 52.6 10 66.7 20 47.6 NS
Clinical lymphadenopathy (cN) 12 21.1 7 46.7 5 11.9 0.009
Pathological node metastasis (pN) 37 64.9 13 86.7 24 57.1 0.040
Subtotal/total thyroidectomy 23 40.4 8 53.3 15 35.7 NS
Modified neck dissection 38 66.7 13 86.7 25 59.5 NS
NS: not significanceBMC Cancer 2009, 9:306 http://www.biomedcentral.com/1471-2407/9/306
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Table 2: Risk factor analysis for disease free survival (DFS) in 57 TNM stage I pediatric DTC patients.
Univariate Multivariate
HR 95%CI P-value HR 95%CI P-value
Male gender 4.36 1.46-13.0 0.008 4.51 1.31-15.5 0.017
Tumor stage (T3, T4a) 1.06 1.00-1.11 0.050 1.06 1.01-1.12 0.029
Multifocality 3.36 1.19-9.43 0.022 2.14 0.71-6.41 0.175
Clinical lymphadenopathy 3.51 1.27-9.71 0.016 4.77 1.55-14.7 0.006
HR: hazard ratio. CI: confidence interval.
Kaplan-Meier survival curves for disease-free survival (DFS) in 57 TNM stage I pediatric DTC patients according to risk factors,  gender (A), tumor stage (B), multifocality (C), and clinical lymphadenopathy (D) Figure 1
Kaplan-Meier survival curves for disease-free survival (DFS) in 57 TNM stage I pediatric DTC patients accord-
ing to risk factors, gender (A), tumor stage (B), multifocality (C), and clinical lymphadenopathy (D).
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Physical examination is important because thyroid mass
and lymphadenopathy are more common in pediatric
DTC patients. Thyroid mass is found in 31% to 97% of the
pediatric patients [2-8,10,11,13,16-18,22-27,35] and
clinical lymphadenopathy in 12% to 100% [1-
8,10,11,13-20,22-27,29-31,34,35]. However, these mani-
festations are occasionally noticed by parents or medical
experts because they develop asymptomatically in this age
population, resulting in the difficulty of early diagnosis in
pediatric patients. In our series, the thyroid mass was large
(mean: 4.3 cm) and was found in 93.0% of the patients.
Clinical lymphadenopathy was found in 21.1% of the
patients.
Aggressive manifestations at diagnosis are considered the
feature of pediatric patients. In the previous studies,
extrathyroid extension or advanced tumor stage has been
reported to be found in 2.8% to 71% of the pediatric
patients [1-9,12-17,21-28,30,31,33,35], multifocality in
12% to 69% [5,7,12-17,22,24,26,28,31,32], pathological
node metastasis in 32% to 100% [1-14,17,19-28,30-
33,35], and synchronous distant metastasis in 0% to 86%
[1-31,33-35]. Our stage I patients presented with extrath-
yroid extension in 12.3%, advanced tumor stage (T3, T4a)
in 52.6%, multifocality in 31.6%, and pathological node
metastasis in 64.9%. Some authors have suggested that
lung metastasis is significant for disease mortality and the
occurrence of lung metastasis is frequent in patients with
lymph node metastasis [18,20]. Our findings suggest that
advanced tumor stage and clinical lymphadenopathy are
independent risk factors for DFS in stage I patients. Bor-
son-Chazot et al. [15] suggest that limited surgery is
appropriate for pediatric patients with no lymphadenop-
athy.
The possible treatments are the main issue to be debated.
Total thyroidectomy followed by RI therapy has been rec-
ommended as the optimal treatment strategy. However,
the occurrence of surgical complication is associated with
total thyroidectomy, especially in pediatric patients. In the
literature, total thyroidectomy (20% to 100%) has com-
monly been performed in many centers [1-26,28-35]. Per-
manent hypoparathyroidism (0% to 35.7%) and RLN
palsy (0% to 41%) are the major complications that are
usually associated with aggressive surgery [1-7,9,11-
13,17,19,21-26,29-33]. Some authors advocate that total
thyroidectomy by experts is safe and does not increase the
possibility of serious complications [24]. On the other
hand, a conservative or stepwise approach has been rec-
ommended to prevent surgical complications and to
avoid over-surgery for non-advanced disease in pediatric
DTC patients [8,9,22,26,29-34]. Our results suggest that
stage I pediatric patients with no risk factor are considered
candidate for conservative or stepwise treatment.
The clinical discrepancy between advanced tumor mani-
festations or the high rates of recurrent disease and the
low rates of disease mortality has been discussed. In the
literature, recurrences occurred in 0% to 47% of the
patients [2-13,15-17,19,21-33,35]. However, the rates of
disease mortality range from 0% to 5.3% and usually less
than 3.0% in the majority of the reports [1-35]. Thus, even
patients with advanced disease can achieve a better prog-
nosis after treatment. Brink et al. suggest that stage II pedi-
atric patients can be treated with a stepwise approach and
achieve long-term survival [33]. Vassilopoulou-Sellin et
al. also suggest that stage II patients have excellent prog-
nosis because of the high concentration of RI [20]. Samuel
et al. suggest that complete remission of lung metastases
after RI therapy is difficult in some patients, but they usu-
ally have no further disease progression and their mortal-
ity rate is low [34].
Optimal treatment strategy and significant risk factors for
stage I pediatric DTC patients are not well established.
Therefore, we analyzed the risk factors in TNM stage I
patients. Total thyroidectomy, node dissection, RI ther-
apy, and TSH suppression therapy are considered superior
treatment options for pediatric DTC patients in many
centers. However, less aggressive treatments are also rec-
ommended in other centers. Newman et al. [21] suggested
that the selection of the extent of thyroidectomy is war-
ranted, i.e., lobectomy for localized tumor and subtotal or
total thyroidectomy for extensive tumor. We consider that
the appropriate treatment strategy should be selected to
handle primary or recurrent disease and to avoid surgical
complications according to risk factors. Such considera-
tions would improve the DFS and the patient's quality of
life in pediatric age population. Our results suggest that
male gender, advanced tumor stage, and clinical lym-
phadenopathy are risk factors for DFS in TNM stage I pedi-
atric DTC patients. In the literature, advanced tumor stage,
multifocality, lymphadenopathy, distant metastasis, and
lower patient age are considered major risk factors for
worse prognosis [6,11,14-17,20,21]. Male gender is also a
risk factor in pediatric patients [2,11,14]. Thus, TNM stage
I pediatric patients may be categorized separately into dif-
ferent substage groups according to risk factors, for exam-
ple stage IA or stage IB, and a conservative or stepwise
approach may be acceptable in pediatric patients without
risk factors.
Finally, long-term follow-up is considered essential to
evaluate outcomes in pediatric patients [6,35]. A shorter
follow-up period may result in inappropriate decision
making of the treatment strategy. In the literature, the
durations of follow-up period range from 3.8 to 27.6 years
[1-6,9-29,31-35]. The mean follow-up period in our study
was 17.4 years, which is considered sufficient for evaluat-
ing outcomes in pediatric patients.BMC Cancer 2009, 9:306 http://www.biomedcentral.com/1471-2407/9/306
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Conclusion
Male gender, advanced tumor stage, and clinical lym-
phadenopathy are risk factors for DFS in TNM stage I pedi-
atric DTC patients, although many patients with
recurrence can achieve disease-free after additional treat-
ments. Aggressive treatment (total thyroidectomy with
node dissection followed by RI therapy) is appropriate for
stage I pediatric patients with risk factors, whereas con-
servative approach may be acceptable for those without
risk factors.
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